Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-018 for prevention of postoperative Crohn's disease recurrence
NL-OMON48150Phase 2Withdrawn
- Sponsor
- Takeda
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing TAK-018 with Placebo (2 arms). Primary endpoint: Safety and tolerability of TAK-018. Planned start Sep 2019; status: withdrawn.
02
Drugs
sibofimloc
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON48150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48150.